@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix Protein: . @prefix hgnc: . @prefix geneProductOf: . @prefix mesh: . @prefix occursIn: . @prefix species: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 geneProductOf: hgnc:3176; a Protein: . sub:_2 geneProductOf: hgnc:9718; a Protein: . sub:_3 occursIn: mesh:D005347, species:9606; rdf:object sub:_2; rdf:predicate belv:increases; rdf:subject sub:_1; a rdf:Statement . sub:assertion rdfs:label "p(HGNC:EDN1) -> p(HGNC:PXN)" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_5; pav:version "1.4" . sub:_4 prov:value "Figure 8. Endothelin induces {alpha}-SMA, paxillin, moesin, and ezrin expression; SSc fibroblasts overexpress {alpha}-SMA, paxillin, moesin, and ezrin in a manner that is dependent on endogenous ET-1 signaling. Normal and SSc fibroblasts were treated with and without 100 nM ET-1 (24 h) as indicated in the presence or absence of bosentan or wortmannin. Cell layers were harvested, and equal amounts of protein were subjected to SDS-PAGE and Western blot analysis with anti-{alpha}-SMA, anti-paxillin, anti-moesin, and anti-ezrin antibodies, as indicated. As a loading control, Western analysis with an anti-GAPDH antibody also was performed."; prov:wasQuotedFrom pubmed:15047866 . sub:_5 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:15047866; prov:wasDerivedFrom beldoc:, sub:_4 . } sub:pubinfo { this: dct:created "2014-07-03T14:30:22.126+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }